Group Art Unit: 1642

Examiner: RAWLINGS, S.



TED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)

Mads N. HOLTEN-ANDERSEN et al.

Application No.:09/546,573

Filed: April 10, 2000

For: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES

TYPE-1 (TIMP-1) AS A CANCER MARKER

INFORMATION DISCLOSURE STATEMENT

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office Washington, DC 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully request consideration of the documents listed on the attached Form PTO-1449 including a pending patent application, which is a continuation-in-part of this patent application. Copies of the documents listed are also enclosed.

Applicants respectfully request that the Examiner consider the documents cited on the Form PTO-1449 and that the Examiner indicate that the documents have been considered in this application by returning a copy of the Form PTO-1449 with the Examiner's initials in the left column per MPEP 609.

Applicants respectfully point out that the submission of the enclosed documents in this IDS is not an admission that they are prior art or that they are material to patentability of any claims of the application.

07/03/2002 AOSNAH1 00000059 09546573

01 FC:126

180.00 OP

This Information Disclosure Statement is submitted after the first Office Action on the merits, but before mailing of a final Office Action. A check for \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed.

If any additional fees are incurred upon the filing of this Information Disclosure Statement, including any petition fees, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS

Date:

June 28, 2002

By:

Stanislaus Aksman

Registration No. 28,562

1900 K Street, N.W., Suite 1200 Washington, D.C. 20006-1109

Telephone: (202) 955-1500 Facsimile: (202) 778-2201

JUL (KECE
8 2002	VED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK PFPISE								CE	ATTY. DOCKET NO.:				SERIAL NO.:			
(REV. 7-80) PATENT AND TRADEMARK EFFICE									EFPISE	59866.000002				09/546,573		
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \								F .C.	INVENTOR'S NAME:			EXAMINER:				
LIST OF MATERIALS CITED BY APPLICANT							Mads N. HOLTEN-ANDERSEN et al.			S. Rawlings						
10 ann							2000	FILING DATE:			GROUP:					
(Ils several sheets if nec sebry) JUN 2.0 too							April 10, 2000			1642						
(Us several sheets if nec ssary) JUN 2 8 7002 FILING DATE: GROUP: April 10, 2000 1642																
ATENT DOCUMENTS																
*EXAMINER INITIAL			DOCUMENT NUMBER FI					}	FILING DA			CLAS	SS	SUBCLASS	FILING DATE	
	Α	10/	1	1	7	0	3	0	04/08/02		M. Holton-Andersen et al.					
-																
							<u> </u>	1	<u> </u>		1		<u> </u>		-	
1.								F	OREIGN PA	TEN	T DOCUME!	NTS				
		DOCUMENT NUMBER DATE								C	COUNTRY CLASS SUBC			ASS TRANSLATION		
													YES	NO		
		 														
	-	<u> </u>														
		<u> </u>							L	1		<u> </u>				
OTHER MATERIALS (Including Author, Title, Date, Pertinent Pages, Etc.)																
	В	Tracy A. Plumpton et al.; Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (Free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP 1 and CRP in serum; Elsevier Science B.V.; pp. 137-154; 1995														
	С	Zeng, Z.S. et al.; Abstract #2038: High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer, as determined by enzyme-linked immunosorbent assay (ELISA), correlate with poor outcome; Proceedings of the American Association for Cancer Research, Vol. 39; p. 298; March 1998														
	<u> </u>															
EXAMINER		DATE CONSIDERED														
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in																

1 CENTER 1600/2900